Remdesivir treatment for patients with moderate to severe COVID-19

HASANOĞLU, İMRAN; Guner, Rahmet; Celik, Ilhami; KANAT, FİKRET; Batirel, Ayse; TELLİ DİZMAN, GÜLÇİN; Eren, Esma; Sevgi, Dilek; Bozkurt, Ilkay; Yasar, Kadriye; Senoglu, Sevtap; KAZAK, ESRA; KARAALİ, RIDVAN; Celikbas, Aysel; PULLUKÇU, HÜSNÜ; Cagatay, Arif; ÜNAL, SERHAT; Erdinc, Sebnem; Tabak, Ömer; Gül, Ahmet; Alp, Emine

doi:10.55730/1300-0144.5387

Remdesivir treatment for patients with moderate to severe COVID-19

HASANOĞLU İ., Guner R., Celik I., KANAT F., Batirel A., TELLİ DİZMAN G., ...Daha Fazla

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.4, ss.880-887, 2022 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 52 Sayı: 4
Basım Tarihi: 2022
Doi Numarası: 10.55730/1300-0144.5387
Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.880-887
Anahtar Kelimeler: COVID-19, remdesivir, antiviral, treatment, mortality
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
İstanbul Üniversitesi Adresli: Evet

Özet

Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment.